Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, June 2008, p. 2223-2225, Vol. 52, No. 6
0066-4804/08/$08.00+0 doi:10.1128/AAC.01410-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Daptomycin Exerts Bactericidal Activity without Lysis of Staphylococcus aureus
Nicole Cotroneo,1
Robert Harris,2
Nancy Perlmutter,3
Terry Beveridge,2,4,
and
Jared A. Silverman1*
Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421,1
University of Guelph, Guelph, Ontario, Canada N1G 2W1,2
Howard M. Shapiro, M.D., P.C., West Newton, Massachusetts,3
MicroTEM, Inc., Elora, Ontario, Canada N0B 1S04
Received 31 October 2007/
Returned for modification 28 December 2007/
Accepted 24 March 2008

ABSTRACT
The ability of daptomycin to produce bactericidal activity against
Staphylococcus aureus while causing negligible cell lysis has
been demonstrated using electron microscopy and the membrane
integrity probes calcein and ToPro3. The formation of aberrant
septa on the cell wall, suggestive of impairment of the cell
division machinery, was also observed.

TEXT
Many antibiotics derive bactericidal activity from their ability
to lyse cells, which may cause liberation of potent proinflammatory
bacterial components, resulting in the generation of a robust
innate immune response that can potentially cause harm to the
host (
8). The lipopeptide antibiotic daptomycin is active against
a wide range of gram-positive bacteria (Cubicin prescription
information, 2005; Cubist Pharmaceuticals, Lexington, MA) (
4)
and is believed to possess a novel mechanism of action that
does not involve cell lysis. Instead, the lipophilic acyl tail
of daptomycin is inserted into the cytoplasmic membrane of the
bacterium, leading to potassium efflux; destruction of the ion-concentration
gradient; membrane depolarization; inhibition of protein, DNA,
and RNA synthesis; and finally cell death (Cubicin prescription
information, 2005; Cubist Pharmaceuticals, Lexington, MA) (
5,
11,
13). Daptomycin is rapidly bactericidal in vitro against
Staphylococcus aureus at low multiples of the MIC (
12). Here,
we demonstrate the bactericidal activity of daptomycin against
S. aureus in the absence of cell lysis. (Portions of this work
were presented previously at the 43rd Interscience Conference
on Antimicrobial Agents and Chemotherapy [
10].)
Cell lysis was initially monitored by measuring optical density during log-phase time kills. Late-exponential-phase cultures (approximately 108 CFU/ml) were used to allow samples to be obtained for transmission electron microscopy (TEM). Staphylococcus aureus ATCC 29213 was grown overnight in calcium-supplemented Mueller-Hinton broth (MHBc; 50 mg/liter Ca2+) and subcultured 1:1,000 into fresh MHBc. Cultures were grown at 37°C with shaking (200 rpm) to an optical density at 600 nm (OD600) of 0.3 to ensure sufficient biomass for fixation and processing. Daptomycin was added at multiples (1x to 8x) of the MIC (0.5 µg/ml). At the indicated time points, samples were removed, OD600 and number of CFU/ml were measured as previously described (7), and cells were pelleted and resuspended in 1 ml MHBc plus 2.5% (vol/vol) glutaraldehyde. Glutaraldehyde-fixed samples were postfixed in 2.0% (wt/vol) osmium tetroxide, followed by en bloc staining with 2.0% (wt/vol) uranyl acetate. The cells were then dehydrated through an ethanol series and embedded in LR White resin. Samples were thin sectioned and stained by uranyl acetate; lead citrate TEM was performed using a LEO 912AB microscope under standard operating conditions at 100 kV, with a liquid nitrogen anticontaminator in place.
As shown in Fig. 1, at 4 µg/ml, daptomycin was rapidly bactericidal, producing a >1,000-fold decrease in viability in less than 120 min, with no concomitant drop in OD600. (Daptomycin displays a well-described inoculum effect [1]; 4 µg/ml is approximately twice the concentration needed to arrest growth at this cell density.) In contrast, OD600 decreased by approximately 50% in cultures treated with the pore-forming antibiotic nisin at a 1x MIC, while viability decreased approximately 200-fold.
Lack of lysis was confirmed by TEM (Fig.
2). There is little
evidence of lysis visible in the population of cells treated
for 60 min at 4 µg/ml. These results are consistent with
those previously reported using scanning electron microscopy
(
13). Interestingly, >90% of cells display altered cell wall
morphology consistent with aberrant division septa.
In addition to the assays described above, the integrity of
the
S. aureus plasma membrane was examined using two fluorometric
methods: calcein release and ToPro3 uptake. For the calcein-release
assay (
6), cells are loaded with the membrane-permeant fluorescent
dye calcein-AM. Following uptake, calcein-AM is cleaved to form
the membrane-impermeant dye calcein. Release of calcein is monitored
fluorometrically following exposure to antibiotics and serves
as a marker for membrane damage and cell lysis. As shown in
Fig.
3, daptomycin treatment produces rapid bactericidal activity
without significant calcein release, consistent with a lack
of lysis or even significant structural damage to the cytoplasmic
membrane. This is in contrast to lysostaphin, which is bactericidal
through the destruction of the
S. aureus cell wall and leads
to a similar drop in recoverable CFU, but with much greater
calcein leakage. The bactericidal activity of the pore-forming
antibiotic nisin is also accompanied by significant calcein
release. Similar results were obtained using ToPro3, a membrane-impermeant
dye whose fluorescence increases significantly in the presence
of DNA; increased fluorescence is considered to be a sign of
membrane permeability. ToPro3 levels were measured by flow cytometry
(Fig.
4) (
9). Fluorescence levels were similar in control and
daptomycin-treated cells, despite a 1,000-fold loss of viability
(not shown). Cells treated with another nonlytic antibiotic
(ciprofloxacin) also displayed control-like values, in sharp
contrast to those treated with the pore-forming agent nisin.
Interestingly, treatment with both the proton ionophore CCCP
and the calcium ionophore A23187 actually reduced fluorescence
relative to that of untreated controls, suggesting that these
agents either decrease normal levels of membrane permeability
or interfere with some level of active transport (import or
efflux) of ToPro3.
The bactericidal ability of daptomycin without cell lysis may
have beneficial clinical consequences through the reduced release
of proinflammatory bacterial components. For example, daptomycin
treatment of methicillin-resistant
S. aureus-infected macrophages
leads to a 50% reduction in the production of proinflammatory
cytokines, such as tumor necrosis factor alpha, compared with
vancomycin treatment (
2). Similarly, the potential for a lessened
inflammatory response compared to that for ceftriaxone has recently
been observed in an experimental model of pneumococcal meningitis
(
3). Further clinical studies are needed to confirm these findings
and determine the effect that a lessened inflammatory response
might have in humans.

ACKNOWLEDGMENTS
This article is dedicated to the memory of the late Terry J.
Beveridge, scholar and colleague.

FOOTNOTES
* Corresponding author. Mailing address: Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, MA 02421. Phone: (781) 860-8405. Fax: (781) 861-1154. E-mail:
Jared.Silverman{at}Cubist.com 
Published ahead of print on 31 March 2008. 
Deceased. 

REFERENCES
1 - Benson, C. A., F. Beaudette, and G. Trenholm. 1987. Comparitive in vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against Gram-positive organisms. J. Antimicrob. Chemother. 20:191-196.[Abstract/Free Full Text]
2 - English, B. K., E. M. Maryniw, A. J. Talatin, and E. M. Meals. 2005. Reduced macrophage tumor necrosis factor (TNF) secretion in response to Staphylococcus aureus (SA) isolates exposed to daptomycin compared with vancomycin or oxacillin. Abstr. Pediatric Academic Societies' Annual Meeting, Washington, DC. abstr. 507.
3 - Grandgirard, D., C. Schurch, P. Cottagnoud, and S. L. Leib. 2007. Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Antimicrob. Agents Chemother. 51:2173-2178.[Abstract/Free Full Text]
4 - King, A., and I. Phillips. 2001. The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. J. Antimicrob. Chemother. 48:219-223.[Abstract/Free Full Text]
5 - Lakey, J. H., and M. Ptak. 1988. Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes. Biochemistry 27:4639-4645.[CrossRef][Medline]
6 - Lichtenfels, R., W. E. Biddison, H. Schulz, A. V. Vogt, and R. Martin. 1994. CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J. Immunol. Methods 172:227-239.[CrossRef][Medline]
7 - Mascio, C. T. M., J. D. Alder, and J. A. Silverman. 2007. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob. Agents Chemother. 51:4255-4260.[Abstract/Free Full Text]
8 - Nau, R., and H. Eiffert. 2005. Minimizing the release of proinflammatory and toxic bacterial products within the host: a promising approach to improve outcome in life-threatening infections. FEMS Immunol. Med. Microbiol. 44:1-16.[CrossRef][Medline]
9 - Novo, D. J., N. G. Perlmutter, R. H. Hunt, and H. M. Shapiro. 2000. Multiparameter flow cytometric analysis of antibiotic effects on membrane potential, membrane permeability, and bacterial counts of Staphylococcus aureus and Micrococcus luteus. Antimicrob. Agents Chemother. 44:827-834.[Abstract/Free Full Text]
10 - Silverman, J., B. Harris, N. Cotroneo, and T. Beveridge. 2003. Daptomycin (DAP) treatment induces membrane and cell wall alterations in Staphylococcus aureus, abstr. CI-2155. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
11 - Silverman, J. A., N. G. Perlmutter, and H. M. Shapiro. 2003. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:2538-2544.[Abstract/Free Full Text]
12 - Thorne G. M., and J. Alder. 2002. Daptomycin: a novel lipopeptide antibiotic. Clin. Microbiol. Newsl. 24:33-40.[CrossRef]
13 - Wale, L. J., A. P. Shelton, and D. Greenwood. 1989. Scanning electron microscopy of Staphylococcus aureus and Enterococcus faecalis exposed to daptomycin. J. Med. Microbiol. 30:45-49.[Abstract/Free Full Text]
Antimicrobial Agents and Chemotherapy, June 2008, p. 2223-2225, Vol. 52, No. 6
0066-4804/08/$08.00+0 doi:10.1128/AAC.01410-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Hachmann, A.-B., Angert, E. R., Helmann, J. D.
(2009). Genetic Analysis of Factors Affecting Susceptibility of Bacillus subtilis to Daptomycin. Antimicrob. Agents Chemother.
53: 1598-1609
[Abstract]
[Full Text]
-
Sarig, H., Rotem, S., Ziserman, L., Danino, D., Mor, A.
(2008). Impact of Self-Assembly Properties on Antibacterial Activity of Short Acyl-Lysine Oligomers. Antimicrob. Agents Chemother.
52: 4308-4314
[Abstract]
[Full Text]
-
Hobbs, J. K., Miller, K., O'Neill, A. J., Chopra, I.
(2008). Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J Antimicrob Chemother
62: 1003-1008
[Abstract]
[Full Text]
-
Hawkey, P. M.
(2008). Pre-clinical experience with daptomycin. J Antimicrob Chemother
62: iii7-iii14
[Abstract]
[Full Text]